A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers
Osteoarthritis

About this trial
This is an interventional treatment trial for Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Healthy male subjects aged 18-55 years inclusive (Parts A and C); healthy male and female subjects aged 18-55 years inclusive (Part B); healthy male and female subjects aged 65 and over (Part D)
- Subjects with a body mass index of 18.0-30.0 kg/m2 inclusive
Exclusion Criteria:
- Subjects who have a clinically relevant history or presence of any clinically significant disease or disorder
- Current smokers or those that have smoked or used nicotine products within 6 months of the Screening visit
Sites / Locations
- Aalborg Clinical Site
- Nottingham Clinical SIte
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Arm 8
Arm 9
Arm 10
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental
Placebo Comparator
Experimental: ONO-4474 Part A1
Experimental: ONO-4474 Placebo Part A1
Experimental: ONO-4474 Part A2
Experimental: ONO-4474 Placebo Part A2
Experimental: ONO-4474 Part B
Experimental: ONO-4474 Placebo Part B
Experimental: ONO-4474 Part C
Experimental: ONO-4474 Placebo Part C
Experimental: ONO-4474 Part D
Experimental: ONO-4474 Placebo Part D
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo